Related Experiment Video
Updated: Aug 14, 2026
An “All-laser” Endothelial Transplant
Published on: July 6, 2015
Laser in situ keratomileusis in patients with diabetes
Ioannis Halkiadakis1, Nadav Belfair, Howard V Gimbel
1Gimbel Eye Centre, Calgary, Alberta, Canada.
Purpose:
To study the outcomes of laser in situ keratomileusis (LASIK) in patients with well-controlled diabetes mellitus.
Setting:
Gimbel Eye Centres, Calgary and Edmonton, Canada.
Methods:
The charts of all patients with diabetes who had LASIK surgery at the Gimbel Eye Centres were reviewed retrospectively. Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), final refraction, and complications were assessed.
Results:
Twenty-four patients (16 men and 8 women) were identified. Mean patient age was 42 years (range 24 to 57 years). Seventeen patients had diabetes type II, and 7 had diabetes type I. Mean preoperative spherical equivalent (SE) was -4.88 +/- 2.13 diopters (D) (range +1.625 to -9.00 D). Median follow-up was 6 months (range 4 to 44 months). No eye lost BSCVA. Twenty-nine eyes (63%) achieved UCVA 20/25 or better, and 31 eyes (67%) were within +/-0.5 D of the intended refraction after the first LASIK surgery. Retreatment was required in 13 eyes (28.3%) because initial surgery was not adequate to correct the refractive error. At the last follow-up visit, 40 eyes (87%) achieved UCVA of 20/25 or better and 43 eyes (93.5%) were within +/-0.5 D of the intended refraction. Three eyes (6.5%) developed an epithelial defect after surgery, and secondary epithelial ingrowth developed in 2 of these eyes. No advancement of diabetic retinopathy was noticed in any eye at the end of the follow-up period.
Conclusions:
Laser in situ keratomileusis surgery was safely performed in patients with well-controlled diabetes. Enhancement may often be required for optimal correction.
